Abstract
Recently the treatment programs for childhood acute myeloid leukemia (AML) have become more effective, not only in achieving a higher percentage of induction responses but also in the improvement of duration of the first remission [7, 9, 12], Because AML in children is rare — about 80 new cases per year are expected in West Germany and West Berlin – it is necessary to cooperate in multicenter trials to gain experience and to establish the value of new therapies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
